Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity
about
Mechanisms of viral entry: sneaking in the front doorThe GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family FlaviviridaeMonoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignThe hepatitis C virus glycan shield and evasion of the humoral immune responseAnalysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant PatientsCharacterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C VirusIsolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C VirusStructural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoproteinMass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycansHepatitis C Virus (HCV)-Induced Immunoglobulin Hypermutation Reduces the Affinity and Neutralizing Activities of Antibodies against HCV Envelope ProteinIn vitro selection of a neutralization-resistant hepatitis C virus escape mutantRole of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopeniaIdentification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C VirusHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateAn anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infectionCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designThe hepatitis C virus E1 glycoprotein undergoes productive folding but accelerated degradation when expressed as an individual subunit in CHO cells.Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing.Hepatitis C virus is primed by CD81 protein for low pH-dependent fusionMapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive PropertiesCooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoproteinBroad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV InfectionRecent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.Prospects for prophylactic hepatitis C vaccines based on virus-like particlesHepatitis C virus evasion mechanisms from neutralizing antibodiesVirus-neutralizing antibodies to hepatitis C virus.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.Mouse monoclonal antibody towards e1 specific epitope blocks viral entry and intracellular viral replication in vitro.Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships.Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry.Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.
P2860
Q22252690-EC497DDA-751A-4AEC-9E14-0DC65563A564Q24609524-2FA01E4C-B0F6-4F07-B2C6-17B32B475C06Q26783378-B3FC605E-46D9-49C3-8D8C-AC60A02ECD27Q26801759-2265244B-83F7-4C96-9D0A-4DE9D26EB2F8Q27023390-AE93B382-B5EE-4D71-B4C0-98A25F2B3BDAQ27472672-81B1562A-D66D-46B7-A2DD-AD5EBFB97EEAQ27473046-AB215228-11DE-4AC0-AB9C-8577A246D805Q27481024-CE60A768-95AF-4CD6-ABFB-8C5E4C3DEEDFQ27485325-5B9A515E-3369-4C9E-9AA5-9D61373D6E18Q27485636-282225BB-B663-4CA2-A93C-A58D65A820A0Q27485679-C5C351AC-A13A-4109-AFC2-B18CADBAE7D2Q27486411-9E8E50F4-6067-40B2-9FC0-982377717E21Q27487549-C0046F83-85CB-4AF6-A23A-FAE845490938Q27488342-55CEE887-8905-4618-AA0D-64448CD28F05Q27490467-DA264AB1-1EAE-45C5-967C-6A4C6F018AA0Q28482261-58D7DE04-A1F4-4257-98F1-2B4C9232B774Q30371674-65F7E2C2-B384-4B1A-9712-D3A31973CD74Q30374314-EF950C8E-AC4D-46BA-B140-6F0278CA2AF4Q34000089-8BE9F60A-92E8-4578-AEA2-BEF2462625A0Q34016463-DAB779C2-C353-44AB-B249-D726BB29E349Q34262165-F420F6C9-D702-4602-86CE-57548CCBF078Q34481429-E1DE3220-9177-4020-9609-E3BD4AC0DE74Q34594027-D1A7B067-0F31-4747-8948-E8FE52DD0A79Q35182834-FE347F9E-8131-435B-9230-0BB1DC3789E4Q35274913-5878EE51-6DEF-4CCF-AEAE-CA6245C68B36Q35912053-3DAEB61D-22FB-4123-9BFB-88FFA9F0A6AAQ35953659-0699F681-ABC9-49EA-9F61-87F974FD3523Q36506935-5585A37E-062B-4D7F-93D8-9E5EA3A73F11Q36811958-59590841-7480-4ED8-8260-8428726FE9F8Q36956517-F81514B6-846D-4009-B69E-B9D48359A59EQ37505405-1DA18DFC-BC92-4C9C-AACB-DB5E40D34F2CQ37967737-56C92869-2AB0-47AA-96D0-B2F5CD0A4783Q38104471-DCA781F2-40E1-4C7A-9314-113BF9233376Q38128299-4551F169-8EB5-4C7F-B6E2-E8E0BB0B135AQ38234934-2CDF5359-2942-4556-97BF-13675320613EQ39092405-366C4221-C409-4060-A980-963D77CB54EDQ39520011-34ACFCBB-1CD0-43BA-B945-51392F222F34Q39545671-6B673775-0773-4062-BB74-98844150AA7EQ39602767-56D93847-657A-4C29-8B2F-54DD22965239Q40286085-E8DDE8E1-707A-4728-9E69-040664578D12
P2860
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Human monoclonal antibody to h ...... tachment and viral infectivity
@ast
Human monoclonal antibody to h ...... tachment and viral infectivity
@en
Human monoclonal antibody to h ...... tachment and viral infectivity
@nl
type
label
Human monoclonal antibody to h ...... tachment and viral infectivity
@ast
Human monoclonal antibody to h ...... tachment and viral infectivity
@en
Human monoclonal antibody to h ...... tachment and viral infectivity
@nl
prefLabel
Human monoclonal antibody to h ...... tachment and viral infectivity
@ast
Human monoclonal antibody to h ...... tachment and viral infectivity
@en
Human monoclonal antibody to h ...... tachment and viral infectivity
@nl
P2093
P2860
P1433
P1476
Human monoclonal antibody to h ...... tachment and viral infectivity
@en
P2093
Steven K H Foung
Sudhir Paul
T Jake Liang
Vicky M H Sung
Zhen-Yong Keck
P2860
P304
P356
10.1128/JVI.78.13.7257-7263.2004
P407
P577
2004-07-01T00:00:00Z